Archive for August, 2009
CRi OosightTM Imaging System a Key to Breakthrough Gene Replacement Method With Potential To Prevent Inherited Mitochondrial Diseases
Woburn, Massachusetts – August 27, 2009
U.S. researchers using CRi’s OosightTM imaging system have developed a gene transfer technique that has potential to prevent inherited diseases passed on from mothers to their children through mutated DNA in cell mitochondria. The research, which demonstrated the technique in rhesus monkeys, appears in the Aug. 26 issue of the journal Nature.
The group, headed by Dr. Shoukhrat Mitalipov of the Oregon National Primate Research Center and the Oregon Stem Cell Center, extracted the nuclear DNA from the mother’s egg, guided by the Oosight system, and transplanted it into another egg that had the nucleus removed. The technique allowed the mother to pass along her nuclear genetic material to her offspring without her mitochondrial DNA. The eggs were fertilized and transplanted into surrogate mothers, resulting in the birth of four apparently healthy monkeys. Defects in DNA of mitochondria, the cell’s “power plants,” are associated with a wide range of human diseases.
The Oosight system solved a key problem in avoiding damage to the nuclear DNA during the transfer procedure by providing a non-invasive imaging technique for visualizing the genetic material. Traditional visualization methods employ a stain or involve exposure to ultraviolet light, either of which can damage DNA. The Oregon team had used the Oosight system in previous research, published in Nature in 2007, that provided a foundation for the current study. In that research, they cloned rhesus monkey embryos and used them to create embryonic stem cells.
The Oosight system uses polarized light to generate high-contrast, real-time images of biological features such as the spindle apparatus housing the chromosomes and other filamentous structures within the egg, such as the multi-layer zona pellucida, without the addition of toxic stains or labels, while simultaneously generating useful quantitative data of their structural composition.
Two of the four offspring, Spindler and Spindy, were named after the spindle, which is what the Oosight system is used to visualize.
“This study underscores the potential of the Oosight system to advance reproductive medicine and highlights the enabling capabilities or our polarized light technology,” said George Abe, president and CEO of CRi.
“With this advance, the Oosight imaging system, which is already widely used in fertility clinics, has offered new insights and possibilities into reproductive health and medicine,” said Gary Borisy, director and CEO of the Marine Biological Laboratory (MBL) in Woods Hole, MA.
The Oosight system is based on imaging technology originally developed by MBL scientists Rudolf Oldenbourg and Michael Shribak, working in collaboration with David Keefe, M.D., of the University of South Florida College of Medicine.
In In Vitro Fertilization (IVF) the Oosight system is used as an aid to intracytosplasmic sperm injection (ICSI). The system not only provides assurance that the genetic material is not damaged by the injection needle, but it can also be used as a measurement tool to assess egg viability in both fresh and frozen eggs. Data show that an egg with a weak or malformed spindle and inner layer zona as measured with the system is much less likely to result in pregnancy.
Other scientists have welcomed news of the advance. Mitochondria-expert Douglas Wallace of the University of California, Irvine, said “results were exciting” and the technique is “potentially very interesting.” Although he did caution that “there are safety issues that are going to need to be addressed before one could think about it in humans.”
The Nature article reported that 15 embryos were transplanted into nine surrogate mothers; three became pregnant, one with twins, and four offspring were born (only three of these offspring have been reported in the Nature paper) The success rate is similar to that of conventional in vitro fertilization.
See a sample movie of the enucleation process that Dr. Mitalipov used. (10.6 MB avi movie courtesy Dr. Mitalipov, OHSU).
Contact CRi at firstname.lastname@example.org for more details.
Oosight system key to breakthrough gene replacement method
U.S. researchers using CRi's OosightTM imaging system have developed a gene transfer technique that has potential to prevent inherited diseases passed on from mothers to their children through mutated DNA in cell mitochondria. The research, which demonstrated the technique in rhesus monkeys, appears in the Aug. 26 issue of the journal Nature. »
Boston, MA – August 2009 – MCRC is pleased to announce a new investment in Litecontrol Corporation. Founded in 1936, Litecontrol is a leader in the design, development, manufacture, and marketing of innovative, high quality architectural lighting systems. Primary markets for the Company’s products include office buildings, schools, hospitals, laboratories, and libraries throughout North America. The Company designs, develops, fabricates, paints, and assembles its products at two fully integrated manufacturing facilities totaling 450,000 square feet in Hanson and Plympton, Massachusetts. The Company’s manufacturing facilities utilize the latest technologies to ensure that all products maintain the highest quality standards with the least impact on the environment. Litecontrol is a privately held, employee-owned corporation with 200 employee-owners. The Company completed its transition to ESOP ownership in late 2007. Mass. Capital’s recent investment refinanced a portion of the existing ESOP debt, providing near term working capital and a more favorable long term amortization schedule.
August 2009 Newsletter
MCRC is pleased to announce a new investment in Litecontrol Corporation. Founded in 1936, Litecontrol is a leader in the design, development, manufacture, and marketing of innovative, high quality architectural lighting systems. Primary markets for the Company's products include office buildings, schools, hospitals, laboratories, and libraries throughout North America. The Company designs, develops, fabricates, paints, and assembles its products at two fully integrated manufacturing facilities totaling 450,000 square feet in Hanson and Plympton, Massachusetts. »
Breakthrough Collaboration with National Institute of Standards and Technology (NIST) Enables Process Engineers to Save Months of Time and Improve Engineering Accuracy When Developing Chemical Process Models
BURLINGTON, Mass.–(BUSINESS WIRE)–Aug. 12, 2009-– Aspen Technology, Inc. (OTC: AZPN.PK), a leading provider of software and services to the process industries, today announced that AspenTech and the National Institute of Standards and Technology (NIST) have received an R&D 100 Award for innovation in software from R&D Magazine. The breakthrough collaboration gives process engineers out of the box modelling capabilities for a wide-range of chemical processes, saving months of time when estimating and evaluating thermophysical properties of chemical compounds for the design and optimization of process industry plants.
Michael Frenklach, Department of Mechanical Engineering Professor, University of California – Berkeley
“For the first time, engineers worldwide now have a tool that not only assures strict quality control of data delivery, but provides critically evaluated data on demand for state-of-the art chemical process and product design. Combining the NIST ThermoData Engine with AspenTech’s engineering software solutions will undoubtedly lead to the development of highly efficient and environmentally friendly new materials and industrial manufacturing processes within a broad range of industries. This product provides unique opportunities for frontier engineering research in materials science, biotechnology, and in the establishment of new industrial-scale processes using renewable sources of energy.”
Dr. Frederick Dryer, Mechanical and Aerospace Engineering Professor, Princeton University
“Incorporating NIST’s ThermoData Engine into AspenTech’s engineering software is changing the core nature of chemical process and product development. For the first time, this jointly developed software provides the opportunity for process design on-demand. This software represents the first and only chemical process design product currently available that supports the development and modification of products and processes on the basis of an “entire body of knowledge” that is updated continuously. Also of great significance is chemical design and development can now be performed with critically evaluated thermophysical and thermochemical properties characterized by the most comprehensive measure of reliability.”
Dr. Navin Patel, Senior Engineer/Program Manager – Technology Solutions Group, QinetiQ North America Operations LLC
“The combination of the NIST ThermoData Engine with AspenTech’s engineering software represents a giant leap forward in the direction of achieving successful process simulation. For years engineers relied on very limited databanks containing few thousand compounds, leaving them to crude, labor and time-intensive techniques to build the required thermophysical and thermochemical data. With the availability of over 15,000 compounds, process design work can now be done with greater confidence with improved simulation results that cut down the time it takes to bring a new product to market. Through continuous updates of all relevant thermophysical and thermochemical properties, design engineers will be able to spend more time solving problems rather than worrying about the quality of the thermophysical properties data used in the simulation.”
Willie Chan, Senior Vice President of Research & Development, AspenTech
“AspenTech is honored to be recognized by such a prestigious awards program. It is the result of a combination of factors unique to AspenTech – a commitment to R&D investment that is unmatched in engineering and optimization software for the process industries; our long-standing recognition of the importance of properties and thermodynamics in process engineering; our long-term cooperation with NIST, and the deep domain knowledge of our industry-leading experts in process modeling and optimization.”
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.
© 2009 Aspen Technology, Inc. AspenTech, aspenONE, the Aspen leaf logo and the 7 Best Practices of Engineering Excellence are trademarks of Aspen Technology, Inc. All rights reserved. All other trademarks are property of their respective owners.
Source: Aspen Technology, Inc.
AspenTech Wins Prestigious R&D 100 Award for Software Innovation
Aspen Technology, Inc. (OTC: AZPN.PK), a leading provider of software and services to the process industries, today announced that AspenTech and the National Institute of Standards and Technology (NIST) have received an R&D 100 Award for innovation in software from R&D Magazine. The breakthrough collaboration gives process engineers out of the box modelling capabilities for a wide-range of chemical processes, saving months of time when estimating and evaluating thermophysical properties of chemical compounds for the design and optimization of process industry plants. »
August 11, 2009, Woburn, MA– Cambridge Research & Instrumentation, Inc. (CRi) is pleased to announce that Richard K. Brown, Ph.D. and John P. McDonough have joined CRi’s Board of Directors. CRi is a leader in biomedical imaging solutions that analyze disease-specific information from biological and clinical samples.
Dr. Brown has over twenty years experience in the life science industry, with a strong track record of growth and accomplishment in both management and business development roles. He is President & CEO of AVIA Biosystems. Prior to founding AVIA, he was President & CEO of MicroCal (now part of GE Healthcare), the world’s leading supplier of microcalorimeters to the life sciences from 2006-2009, and led its successful sale to GE Healthcare. Prior to that, he held various executive positions at Isis Pharmaceuticals from 2001-2006, including Vice President of Business Development and President of GeneTrove, the functional genomics division of Isis, where he was successful in establishing numerous partnerships with large pharmaceutical companies. Additionally, he held various executive positions at Discovery Partners International from 1995-2001, including President of IRORI where he participated in a successful IPO. Prior to DPI, Dr. Brown held various leadership positions with Zymark Corporation (now Caliper Life Sciences) from 1983-1995.
Mr. McDonough is a seasoned executive with extensive management, financial and M&A experience. He is President, CEO, and Board Director of T2 Biosystems, a venture-backed medical diagnostics company developing point-of-care platforms. Prior to T2, he held numerous executive positions in corporate development and operations at Cytyc Corporation from 2003-2006, including President of Cytyc Development Corporation where he led numerous multi-million dollar acquisitions including the negotiation of the $6.3 billion acquisition of Cytyc by Hologic, and the subsequent integration. Prior to that, he founded and served as CEO and Chairman of the Board for Soundbite Communications from 2000-2003, where he raised several rounds of venture funding and led a successful IPO. Mr. McDonough was also COO of Direct Hit Technologies from 1999-2000 until its sale to Ask Jeeves, President & CEO of Workgroup Technology Corporation from 1997-1999, and held numerous executive positions at Easel Corporation from 1985-1995, including President & CEO, until its successful merger with VMARK Software.
“We are very excited to have entrepreneurial executives as talented as Richard and John join our Board,” says CRi President & CEO George Abe. “I have no doubt that as our company continues to grow, their guidance will contribute greatly to our shareholder value.”
Cambridge Research & Instrumentation, Inc (CRi) is a leader in biomedical imaging, and is dedicated to providing comprehensive solutions that analyze disease-specific information from biological and clinical samples in the combined physiological, morphological, and biochemical context of intact tissues and organisms for a variety of applications. With over 80 patents pending and issued, CRi’s award-winning innovations are being utilized around the world to enable our customers to perform leading research and provide better healthcare.
For more information visit our website at www.cri-inc.com or contact:
President & CEO
Cambridge Research & Instrumentation, Inc. (CRi)
Richard K. Brown, Ph.D. and John P. McDonough Join CRI’s Board of Directors
Cambridge Research & Instrumentation, Inc. (CRi) is pleased to announce that Richard K. Brown, Ph.D. and John P. McDonough have joined CRi's Board of Directors. CRi is a leader in biomedical imaging solutions that analyze disease-specific information from biological and clinical samples. »
“Lion Pride” Challenges Players to Stay at the Top of the Food Chain
WALTHAM, MA, August 10, 2009 – Blue Fang GamesTM, developer of the leading Games for Windows® franchise “Zoo TycoonTM and highly anticipated World of ZooTM for WiiTM, Nintendo DSTM and Windows® PC,” today announced the launch of its first iPhone game titled “Lion Pride“.
“Lion Pride” is an addictive, fast-paced game in which the player controls lions as they stalk their territory and ambush prey. Using simple finger gestures, the player positions their lions, slowly stalks their prey and runs in for the attack. Players can coordinate multiple lions to trap animals or take down larger game. It’s a race against the clock – if the player doesn’t provide enough food for their cubs, they will go hungry and it’s ‘game over’!
“We are very excited to develop and publish our first game for the iPhone platform,” said Hank Howie, President of Blue Fang Games. “Blue Fang sees tremendous potential in applying our unmatched development expertise in animal games to mobile platforms. We’re eager to share the fun and addictive gameplay of ‘Lion Pride’ with iPhone users around the world and look forward to expanding our iPhone portfolio of games.”
For the media, screenshots are available for download at: www.bluefang.com/company/press-info.
About Blue Fang Games
Blue Fang Games is an independent game developer dedicated to pushing the boundaries of interactive entertainment to deliver original and engaging experiences that stand out from the noise on the shelves. Blue Fang’s Zoo TycoonTM franchise has sold over 8 million units worldwide and the studio is now developing World of Zoo which will be released by THQ, Inc this Fall on the Nintendo WiiTM and DSTM and Windows® PC platforms. Founded in 1998, Blue Fang Games is located in Waltham, MA. For more information visit Blue Fang Games on the web at www.bluefang.com.
Blue Fang Games Launches Its First iPhone Game
Blue Fang GamesTM, developer of the leading Games for Windows® franchise "Zoo TycoonTM and highly anticipated World of ZooTM for WiiTM, Nintendo DSTM and Windows® PC," today announced the launch of its first iPhone game titled "Lion Pride". »